Welcome to our dedicated page for InspireMD SEC filings (Ticker: NSPR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on InspireMD's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into InspireMD's regulatory disclosures and financial reporting.
InspireMD, Inc. (NSPR) received an updated ownership report from Rosalind-related investors on an amended Schedule 13G as of 12/31/2025. Rosalind Advisors, Inc., Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P., and portfolio managers Steven Salamon and Gilad Aharon collectively report beneficial ownership of 3,905,743 common shares, or 9.2% of InspireMD’s common stock, based on 42,370,995 shares outstanding as of November 10, 2025.
The group also holds 7,081,361 common shares issuable upon exercise of pre-funded and standard warrants, but these cannot currently be exercised because of a 9.99% “blocker” that prevents exercises which would push holdings above that level. The reporting persons state that the securities are held in the ordinary course of business and not for the purpose of changing or influencing control of InspireMD.
InspireMD Chief Commercial Officer Shane Thomas Gleason reported a series of automatic stock sales to cover taxes on vested restricted stock. Between mid-January and early February 2026, he sold multiple small blocks of InspireMD common stock under a pre-established sell-to-cover instruction.
The filing explains that these transactions were required to satisfy tax withholding obligations tied to restricted stock vesting and were executed pursuant to an automatic sales instruction letter adopted on November 25, 2024, rather than being discretionary trades. After the most recent sale, Gleason beneficially owned 1,139,177 shares of InspireMD common stock directly.
Aberdeen Group plc and abrdn Inc. report a significant institutional holding in InspireMD, Inc. They beneficially own 3,173,364 shares of InspireMD common stock, representing 7.49% of the class. All voting and dispositive power over these shares is shared, with no sole voting or dispositive authority.
The firms state the securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of InspireMD. abrdn Inc. holds the position on behalf of underlying clients that own 5% or more of this security class.
InspireMD, Inc. director Scott R. Ward reported an equity award of common stock. On January 14, 2026, he received 88,053 shares of common stock at a price of $0 per share, characterized as an acquisition. These shares are restricted stock that will vest on January 14, 2027, as long as he continues in service with the company through that date. Following this grant, he beneficially owns 147,846 shares of InspireMD common stock directly.
InspireMD, Inc. reported that Chief Operating Officer Andrea Tommasoli received an award of 226,695 shares of common stock on January 14, 2026. The shares were acquired at a price of $0 per share, indicating a grant of restricted stock rather than an open-market purchase. Following this grant, Tommasoli beneficially owned 954,389 shares of InspireMD common stock directly.
According to the footnote, these shares are restricted stock that vest in three equal annual installments, with one-third scheduled to vest on each of January 14, 2027, January 14, 2028 and January 14, 2028, subject to Tommasoli’s continued service with the company. This structure ties a portion of the executive’s compensation to ongoing employment and future share value.
InspireMD, Inc. director Paul Stuka reported a grant of 132,076 shares of common stock as restricted stock on January 14, 2026. The award was reported at a price of $0 per share and will vest on January 14, 2027, provided he continues to serve, bringing his directly held common shares to 523,704.
The filing also notes 444,195 shares of InspireMD common stock held indirectly through Osiris Investment Partners, L.P. Mr. Stuka is the managing member of the general partner of Osiris and may be deemed to beneficially own these securities, but he disclaims beneficial ownership except to the extent of his pecuniary interest. No transaction occurred with respect to these Osiris-held shares; they are reported for informational purposes.
InspireMD, Inc. reported an equity award to its CEO and President, Marvin Slosman, in the form of 1,114,792 restricted stock units granted on January 14, 2026 at a price of $0 per unit. After this grant, he beneficially owns 3,535,658 InspireMD shares. These restricted stock units vest in three equal annual installments, with one-third vesting on each of January 14, 2027, January 14, 2028, and January 14, 2029, as long as he continues in service with the company.
InspireMD, Inc. director receives restricted stock grant. Director Gary S. Roubin reported an award of 88,053 shares of InspireMD common stock on January 14, 2026. The shares were acquired at a stated price of $0 per share as a stock award, increasing his beneficial ownership to 744,478 common shares held directly. The 88,053 shares are restricted stock that will vest on January 14, 2027, provided he continues to serve through that one-year grant anniversary date.
InspireMD, Inc. reported an equity grant to its Chief Financial Officer. A Form 4 shows CFO Michael Lawless received an award of 226,695 shares of common stock on January 14, 2026 at a price of $0 per share, increasing his directly held stake to 691,695 shares.
The new shares are restricted stock that vest in three equal annual installments, with one-third vesting on each of January 14, 2027, January 14, 2028, and January 14, 2029, as long as he continues in service with the company.
InspireMD, Inc. reported that Chief Commercial Officer Shane Gleason received an award of 453,390 shares of common stock on January 14, 2026 at a price of $0 per share.
These shares are restricted stock that vest in three equal annual installments on January 14, 2027, January 14, 2028 and January 14, 2029, conditioned on his continued service. After this grant, he directly beneficially owns 1,200,371 shares of InspireMD common stock.